Exicure (XCUR) Shares Outstanding (2016 - 2026)
Exicure's (XCUR) quarterly Shares Outstanding (Entity) came in at $6.4 million in Q1 2026, up 0.89% YoY from $6.3 million in Q1 2025, and little changed on a QoQ basis from $6.4 million in Q4 2025.
Exicure (XCUR) Shares Outstanding (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Shares Outstanding (Entity) data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 0.89% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 0.89% YoY) and the FY2025 annual result came in at $6.4 million, up 211.94% from the prior year.
- Shares Outstanding (Entity) held at $6.4 million in Q1 2026, from $6.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $6.4 million in Q1 2026 to a low of $818537.0 in Q1 2022.
- A 5-year average of $2.9 million and a median of $1.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) increased 0.03% — and 2025, when it jumped 265.15%.
- Tracing XCUR's Shares Outstanding (Entity) over 5 years: stood at $993180.0 in 2022, then jumped by 74.2% to $1.7 million in 2023, then rose by 18.1% to $2.0 million in 2024, then surged by 211.94% to $6.4 million in 2025, then increased by 0.0% to $6.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $6.4 million (Q1 2026), $6.4 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | 6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.37 Mn |
| Dec 31, 2025 | 6.30 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | 6.32 Mn |
| Mar 31, 2025 | 6.17 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 923,894.00 |
| Sep 30, 2022 | 992,669.00 |
| Jun 30, 2022 | 900,797.00 |
| Mar 31, 2022 | 806,186.00 |
| Dec 31, 2021 | 590,723.00 |
| Sep 30, 2021 | 587,308.00 |
| Jun 30, 2021 | 586,898.00 |